Erasca (ERAS) Other Non Operating Income (2023 - 2026)
Erasca's (ERAS) quarterly Other Non Operating Income came in at $22000.0 in Q1 2026, up 128.95% YoY from $9609.2 in Q1 2025, and up 159.46% on a QoQ basis from -$37000.0 in Q3 2025.
Analysis
Erasca (ERAS) Other Non Operating Income (2023 - 2026) Analysis & Trends
Erasca (ERAS) has 4 years of Other Non Operating Income data on file, last reported at $22000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 128.95% year-over-year to $22000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82000.0 (changed N/A YoY) and the FY2022 annual result came in at -$257000.0, down 181.85% from the prior year.
- Other Non Operating Income advanced to $22000.0 in Q1 2026, from -$37000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $173000.0 in Q3 2024 to a low of -$76000.0 in Q1 2025.
- A 4-year average of $6600.0 and a median of -$37000.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 453.06% — and 2025, when it plunged 121.39%.
- Tracing ERAS's Other Non Operating Income over 4 years: stood at -$49000.0 in 2023, then jumped by 453.06% to $173000.0 in 2024, then sank by 121.39% to -$37000.0 in 2025, then surged by 159.46% to $22000.0 in 2026.
- The last three Other Non Operating Income figures came in at $22000.0 (Q1 2026), -$37000.0 (Q3 2025), and -$76000.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Erasca | 5.03 Bn | 5.03 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 22,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Mar 31, 2025 | -76,000.00 |
| Sep 30, 2024 | 173,000.00 |
| Sep 30, 2023 | -49,000.00 |